linjc16/ctgov huggingface dataset:
Exogenous Toxicants and Genetic Susceptibility in ALS

Study Overview
=================
Brief Summary
-----------------
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members. The principal objective of this epidemiologic study is to identify environmental and genetic risk factors for ALS. Of primary interest is whether environmental chemicals such as heavy metals, pesticides and organic solvents contribute to the cause of ALS. We also aim to identify genetic factors that contribute to the risk of ALS because individuals with certain genetic traits may be unable to protect against the toxic effects of chemical exposure. Other factors that may protect against the development of ALS, such as dietary antioxidants, are also under investigation. If modifiable factors affecting the risk for ALS could be identified, interventions to delay or even prevent the development of ALS could be developed.

Detailed Description
-----------------
The principal objective of this study is to identify environmental and/or genetic risk factors for amyotrophic lateral sclerosis (ALS). We are addressing this objective by conducting a case-control study of ALS in the Northern California Kaiser Permanente Medical Care Program (KPMCP). Over a four-year period, approximately 175 persons newly diagnosed with ALS will be identified and recruited through physician referrals and computerized mechanisms available within the Kaiser system. The patients with ALS will be compared to a sample of 350 age- and gender-matched persons without ALS from the same membership. Specific study aims are as follows: (1) to investigate the association of ALS with exposure to neurotoxicants including lead, other heavy metals, solvents and pesticides; (2) to determine whether inadequate oxidative defenses for protecting against free-radicals enhance the toxicity of exogenous exposures; (3) to examine the evidence for familial aggregation of neurodegenerative diseases among first-degree relatives of patients with ALS; and (4) to estimate the incidence of ALS in diverse racial and ethnic groups.

Conditions
-----------------
Amyotrophic Lateral Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Individuals with ALS within the Kaiser Permanente population of Northern California, ages 18 years and older, with first diagnosis of ALS in the years 1996-2000. Controls are individuals who are age- and sex-matched to the patients with ALS, also from the Kaiser Permanente population.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney

Study Overview
=================
Brief Summary
-----------------
Previous experimental studies concluded that angiotensin receptor blockers can ameliorate the harmful inflammatory and histological changes after relief of obstruction. Nevertheless, these witnessed effects have not been yet translated into the clinical practice.

Official Title
-----------------
The Effect of Losartan on the Recoverability of Renal Function in Anuric and Oliguric Patients With Unilateral Obstructed Kidney: A Double Blind Randomized Placebo-controlled Trial

Conditions
-----------------
Uropathy, Losartan Adverse Reaction, Uropathy Obstructive

Intervention / Treatment
-----------------
* Drug: Cozaar (Losartan Potassium 25mg)
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: anuric and oliguric patients calculuar ureteral obstruction Exclusion Criteria: anomalous kidney bilateral obstructed kidney history of recent use of angiotensin receptor blockers or angiotensin-converting enzyme inhibitors ASA score of >3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Losartan<br>to receive the medication Cozaar (Losartan Potassium 25mg Merck Sharp & Dohme-UK), | Drug: Cozaar (Losartan Potassium 25mg)<br>* Cozaar (Losartan Potassium 25mg)<br>* Other names: Cozaar;|
| Placebo Comparator: Placebo<br>to receive either placebo | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renographic glomerular filtration rate of the affected kidney. | assessed by radioisotope renography using 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) in ml/min | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum creatinine change | assessed by serum creatnine in mg/dl | 3 months |
GLUCOSAMINE/CHONDROITIN and PHYSICAL THERAPY EFFECTS ON OLDER POPULATION WITH KNEE OSTEOARTHRITIS

Study Overview
=================
Brief Summary
-----------------
to see the effect of glucosamine chondratin sulfate with and without physiotherapy in knee osteoarthritis

Detailed Description
-----------------
it is a randomized control trail to evaluate the effectiveness of glucosamine chondratin sulfate alone and in combination with physiotherapy on knee osteoarthritis

Official Title
-----------------
EFFECTS OF COMBINED GLUCOSAMINE/CHONDROITIN WITH STRUCTURED PHYSICAL THERAPY PROGRAM ON KNEE OSTEOARTHRITIS: A RANDOMIZED CONTROL TRAIL

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Other: Glucosamine Chondroitin
* Combination Product: glucosamine chondritin & Physiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 50 years with radiographic evidence of mild to moderate knee OA (Kellgren Lawrence grade II & III 20) who met the ACR clinical 21, radiographic classification criteria or confirmation of mild to moderate radiographic evidence of knee OA from a personal physician not currently participating in another intervention study Exclusion Criteria: dementia (Mini-Mental State Examination [MMSE]< 24) active cancer other than skin cancer anemia (participants with an hematocrit (HCT)< 32 (or a hemoglobin below10) were excluded due to possible inability to adequately exercise or the increased potential for increased risk for serious adverse cardiovascular events) severe renal insufficiency (serum creat> 2) hepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: two groups
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: control group<br>chondritin sulfate 1500/1200mg | Other: Glucosamine Chondroitin<br>* control group<br>|
| Experimental: experimental group<br>chondritin sulfate plus physiotherapy | Combination Product: glucosamine chondritin & Physiotherapy<br>* experimental group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| WOMAC | higher score means worst patient condition and lower score means better | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SF-36 | higher score means better patient condition and lower score means worst | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OA, Chondratin sulfate, glucosamine, Physiotherapy
Immune Monitoring of Hepatitis C Under DAA Therapy

Study Overview
=================
Brief Summary
-----------------
Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis C infection. In this study cytokine markers will be measured during therapy up to time point SVR 12 an correlated to clinical Parameters and regular laboratory findings.

Official Title
-----------------
Prospective Monitoring of Immune Parameters in Patients With Hepatitis C Under Treatment With Direct Acting Antivirals

Conditions
-----------------
Hepatitis C

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: written consent, age, HCV-RNA positive, DAA therapy Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of IP10 and related cytokines during treatment (ng/ml) | Screening for Biomarkers under DAA Therapy until timepoint SVR 12 (12 weeks treatment plus control 12 weeks after end of Treatment = 24 weeks) | 24 weeks (observation time under and after DAA therapy) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SVR 12 | Eradication of HCV RNA 12 weeks after end of Treatment (Treatment 12 weeks) | 24 weeks (12 weeks treatment plus control 12 weeks after end of treatment) | 
| Change of inflammatory markers (ferritin ng/ml, CRP mg/l, PCT ng/ml) during treatment |  | 24 weeks (observation time under DAA therapy) |
Detection of Area of Ischemia in Patients With Subacute Stroke Via a Hybrid EEG-fNIRS Brain-computer Interface

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to determine whether a combined electroencephalography (EEG) and functional near infrared spectroscopy (fNIRS) recording is able to detect changes in brain activity and blood flow after stroke.

Official Title
-----------------
Detection of Area of Ischemia in Patients With Subacute Stroke Via a Hybrid EEG-fNIRS Brain-computer Interface

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: Combined EEG and fNIRS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with a subacute ischemic stroke with symptom onset within 8 weeks Must have a measurable deficit on the National Institute of Health Stroke Scale (NIHSS) Able to give and sign informed consent Exclusion Criteria: Aphasia Underlying dementia Any chronic neurological disorder Malignancy Non-ambulatory (ambulation with assistance will be included) Modified Rankin Score (mRS) > 3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Combined EEG and fNIRS<br>EEG is electroencephalography. fNIRS is functional near infrared spectroscopy. The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. | Device: Combined EEG and fNIRS<br>* The EEG+NIRS recordings will be obtained via an extended EEG cap that is applied to the subject's head. Changes in neuronal activity and hemodynamics will be measured. The EEG component is the microEEG by BioSignal Group, UA. The fNIRS component is the NIRScout 24x32, NIRx Medizintechnik GmbH, Germany<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with abnormal blood flow as assessed by fNIRS | Abnormal blood flow is determined by comparing a part of the patient's brain not affected by stroke to a part of the patient's brain affected by stroke. | immediately at the time of combined EEG and fNIRS for up to 60 minutes | 
| Number of participants with abnormal neuronal activity as assessed by EEG | Abnormal neuronal activity is determined by comparing a part of the patient's brain not affected by stroke to a part of the patient's brain affected by stroke. | immediately at the time of combined EEG and fNIRS for up to 60 minutes |
Running Retraining to Minimize Braking Forces

Study Overview
=================
Brief Summary
-----------------
The proposed research study aims to investigate whether a gait modification training program to decrease peak braking forces during the stance phase of running will result in a reduction in impact loading and the incidence of running-related injuries among recreational distance runners.

Official Title
-----------------
The Effect of a Gait Modification Training Program on Impact Loading and Running-related Injuries

Conditions
-----------------
Athletic Injuries

Intervention / Treatment
-----------------
* Device: Real-time visual biofeedback during treadmill running


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to commit to a 15-week half-marathon training program Have been running for at least 3 months prior to study commencement Have participated in 2 or less half-marathons previously Ability to run on a treadmill unaided Ability to travel to testing facility for running analysis pre- and post-training program as well as for gait retraining sessions Ability to understand written and spoken English Meet the screening requirements (display less than -0.27BW mean peak braking force at baseline/screening assessment) Exclusion Criteria: Any lower extremity pathology in the previous 3 months or currently have pain in their lower back or lower extremities while running Have undergone hip, knee, or ankle joint surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Real time biofeedback<br>Real-time visual biofeedback of braking forces during a treadmill run. | Device: Real-time visual biofeedback during treadmill running<br>* Real-time biofeedback of braking forces during running<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak Braking Force | The peak horizontal force applied in the posterior direction during the stance phase of running | 15 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Vertical Loading Rate | The average vertical loading rate during stance phase | 15 weeks | 
| Step Length | The average step length | 15 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Running, Biomechanics, Kinetics
Masseter Muscle Activity and Post-operative Pain in a Group of Egyptian Children Treated With Hall Technique Vs Modified Hall Technique

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate postoperative pain and masseter muscle activity in a group of Egyptian children with carious primary molars treated with Hall Vs modified Hall Technique (with proximal and occlusal reduction).

Official Title
-----------------
Masseter Muscle Activity and Post-Operative Pain in A Group of Egyptian Children With Carious Primary Molars Treated With Hall Vs Modified Hall Technique: A Randomised Clinical Trial

Conditions
-----------------
Masseter Muscle Activity

Intervention / Treatment
-----------------
* Diagnostic Test: Modified Hall technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children 5-7 years with carious lower second primary molars Both genders. Systemically and mentally healthy. Exclusion Criteria: History of systemic or mental conditions. Special health care needs who require pharmacological management before dental treatment. Acute dental pain or trauma. Extremely uncooperative children who require being treated under general anesthesia.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Modified Hall technique<br> | Diagnostic Test: Modified Hall technique<br>* The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps<br>|
| Experimental: Hall Technique<br> | Diagnostic Test: Modified Hall technique<br>* The standard Hall technique was later modified with several modifications including occasional/rare use of anesthetic and about 1 mm proximal slice that the preformed metal crown fits without separation, and minimal occlusal reduction of the cusps<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Masseter muscle activity measured by Electromyograph | muscle activity will be measured following the cementation of the crown | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hall technique, Modified Hall technique, Stainless steel crowns
The Application Value of STIC in the Diagnosis of Fetal Complex Congenital Heart Disease

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to use of STIC technology to assist the traditional echocardiography to diagnose the fetal congenital heart disease accurately and then to provide a basis for prenatal counseling.

Detailed Description
-----------------
This is a diagnostic test in Shanghai Xinhua hospital from Nov.2016 to Dec.2017. 265 Cases are gravidas with fetal congenital heart disease diagnosed by echocardiography.Only gravidas who are willing to have complete pregnancy checks and finally delivery or abortion in the hospital are interviewed are eligible for the study. Study participants will be asked for their informed consent.We collect their fetal 2D echocardiography and STIC images every 4-6 weeks during pregnancy and 1 weeks after the baby giving birth we finish their neonatal echocardiography.

Official Title
-----------------
The Application Value of STIC in the Diagnosis of Fetal Complex Congenital Heart Disease

Conditions
-----------------
Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gravida with singleton pregnancy taking fetal echocardiography. No virus infection or drug use history, no harmful substances in the early pregnancy. Complete pregnancy check in the hospital, and finally delivery or abortion in the hospital. On the basis of informed consent，willing to cooperate with our group. Exclusion Criteria: Elderly pregnant women (>35 years old) Twin or multiple pregnancy Pregnant women suffering from mental illness, can't take care of themselves. Fetus diagnosed with other abnormalities (except congenital heart defects)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fetal congenital heart disease cases<br>Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fetal Congenital heart disease | If an enrolled gravida chooses to terminate her pregnancy, autopsy confirmation will be performed ;If the gravida continues her pregnancy, the outcome will be measured by neonatal echocardiography or surgery. | Nov 2016 to Dec 2018 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spatio-Temporal Image Correlation, Complicated congenital heart disease, Echocardiography